PHE is monitoring the effectiveness of COVID-19 vaccines using existing surveillance systems and studies as well as new enhanced surveillance. Vaccine effectiveness is being estimated against a range of outcomes including symptomatic disease, hospitalisations, infection and transmission.
This report presents data on the early effect of vaccination with the Pfizer/BioNTech (BNT162b2) and AstraZeneca (ChAdOx1) vaccines on symptomatic COVID-19, infection and hospitalisation, as well as the population level impact on hospitalisations and deaths.
Ref: PHE publications gateway number: GOV-7777
- Published in
- United Kingdom
